secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0000950170-23-019162
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Biosciences Q1 net loss widens to $38.6M; cash $220.3M, runway into 2025; AdvSM trial expands
--------------------------------------------------------------------------------

- Cash and marketable securities $220.3M at March 31, 2023, down from $259.3M at Dec 31; funding expected into 2025.
- Net loss of $38.6M for Q1 2023 vs $30.6M in Q1 2022; R&D expenses $36.0M (+41% YoY) driven by clinical trials.
- Initiated Part 2 of Phase 2 APEX trial in Advanced Systemic Mastocytosis at 150 mg; enrollment target by end-2024.
- FDA granted Orphan Drug Designation for bezuclastinib in mastocytosis (including SM); ~30,000 annual US diagnoses.
- Upcoming data: PEAK GIST lead-in safety/efficacy at ASCO June 2023; SUMMIT NonAdvSM and APEX Part 1 data in 2H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000095017023019162/0000950170-23-019162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000095017023019162/cogt-20230509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-019162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer